<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kastrati, Adnan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Drug-Eluting Stent Safety — Is it Time to Turn the Page on Barcelona 2006?</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">31-31</style></pages><abstract><style  face="normal" font="default" size="100%">While it is generally agreed that drug-eluting stents (DES) can dramatically reduce the need for revascularization, many believe that the issue remains as to whether the late thrombosis that is seen with DES results in an increase in myocardial infarction and death.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>